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1.

Introduction

Molecular biotechnology may yield biomarkers for many purposes including early detection
of disease, accurate sophisticated diagnosis and monitoring of treatment effect. The development of biomarkers is a relatively recent area of research. Yet, the enormous investment
of resources from public and private sectors testifies to the promise that this approach holds.
The ROC curve is typically used to describe the discriminatory capacity of a marker. However, for most statisticians, their familiarity with ROC methodology is limited. Here we use
an alternative conceptual framework for marker evaluation that has very traditional statistical elements. We show that it has strong ties to ROC analysis and importantly, we describe
some new techniques afforded by this framework.
Two specific problems are considered here. The first problem is to determine if CA-125,
a cancer antigen, discriminates women with benign ovarian tumors from healthy women as
well as it discriminates women with clinically detected ovarian cancers from healthy women.
If so, failure to distinguish benign tumors from ovarian cancer limits the utility of this
marker for both diagnostic and screening purposes. Let Y be the CA-125 measurement.
Previously published data shown in Figure 1 are comprised of {YD̄i , i = 1, ..., nD̄ } for controls,
{Y1j , j = 1, ..., n1} for cases with benign tumors, and {Y2j , j = 1, ..., n2} for cases with ovarian
cancer, where nD̄ = 41, n1 = 24, n2 = 66, and nD = n1 + n2 = 90 (McIntosh et al.,2004).
The second problem is to compare the discriminatory performances of two biomarkers, CA-19-9 and CA-125, for pancreatic cancer. For each of nD = 90 cases with cancer and nD̄ = 51 controls who did not have cancer but had pancreatitis (Wieand et al.,
1989), the biomarkers denoted by (Y1 , Y2 ) are measured. The data are represented as
{(Y1D̄i , Y2D̄i ) , i = 1, ..., nD̄ , (Y1Dj , Y2Dj ) , j = 1, ..., nD }.
1
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In this report, we start by setting these two statistical problems in the new conceptual
framework, without assuming any familiarity with ROC methodology. We develop several
methods for inference including a natural approach to covariate adjustment. Finally we discuss how this framework relates to existing ROC methods and how it provides new methods
for ROC analysis.
2.

Reference Distribution Standardization

The key idea is to use the biomarker distribution in controls as a reference distribution to
standardize marker values. Let F (Y ) denote the cumulative distribution of the marker Y in
the control population. The standardized marker value which we call its percentile value is
percentile value= Q ≡ 100 × F (Y )
This sort of standardization using a reference distribution is already commonplace in laboratory medicine and in clinical medicine. In clinical medicine for example, consider that
weight and height of children are standardized relative to a healthy population of children
of the same age and gender, so that reporting of percentile values is typical in practice.
Suppose without loss of generality that larger biomarker values are associated with disease
(else we can use −Y as the marker). An unusually large value of Y has a percentile value
close to 100. In laboratory medicine a value of Q above 95 or 99 might be flagged as outside
of the normal reference range. A good biomarker would flag most cases as being outside of
the normal range. We propose that the distribution of case percentile values is a natural way
to characterize the discriminatory performance of markers. On the one hand, with a useless
marker the case and control distributions of Y are the same so Q has a uniform (0, 100)
distribution. On the other hand, an ideal marker will place all cases at Q = 100. The closer
the case distribution of Q is to that of the ideal, the better is the marker.
One could compare benign tumors and malignant cancers in regards to their distributions
of the standardized marker values. Substantially smaller values in benign tumor cases would
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indicate that discrimination is not as good for them as it is for malignant cancer cases. An
advantage of the standardization is that it simplifies the problem by essentially reducing the
number of groups from 3 to 2. In a sense, rather than evaluating if there is an interaction on
the marker between disease status and disease type, we need only do a simple two sample
comparison of Q between benign tumor cases and malignant cancer cases.
To compare two markers for discriminating a single set of cases from controls, each marker
would be standardized with respect to its distribution in controls, yielding standardized
values Q1 and Q2 for markers 1 and 2 respectively. If Q1 tends to be larger than Q2, marker
1 is the better marker because for cases it is more indicative of their disease than is marker 2.
The standardization puts the two markers on a common scale where they can be compared
using simple paired comparisons.
Adopting the control distribution as a reference to standardize a biomarker seems like a
natural useful procedure. The approach has been taken in some biomarker studies (Frischancho, 1990; McIntosh et al., 2004), but it has never been formalized as a valid statistical
method. Moreover, since in practice only a finite sample of controls are available, formal
statistical procedures need to acknowledge sampling variability in the reference distribution.
We will develop formal methods for inference here.
We can estimate F either empirically or parametrically with control data {YD̄i , i =
1, ..., nD̄ }. Write F̂ for the estimator which in the case of parametric estimation can also
be written Fθ̂ where θ̂ is the estimated parameter for the model Fθ . Even if marker values
among cases are independent, their estimated standardized values, Q̂j = 100 × F̂ (Yj ), are
not independent because of their common dependence on F̂ . This makes inference somewhat
challenging.

3
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3. Comparing Benign Tumors versus Ovarian Cancers
3.1 Comparing Means
3.1.1 Unconditional Test

Let Qz (Q̂z ) denote the percentile value (estimated) for the

z th group of cases, with mean E(Qz ), z = 1, 2. Let ∆ = E(Q1) − E(Q2). The difference in
ˆ = Q̂ − Q̂ can serve as the basis of a test statistic. Let nD̄ , n1 , n2 be the
sample means ∆
1
2
numbers of subjects in the control group and the 1st and 2nd case groups respectively. The
next theorem is proved in supplementary appendices.
Theorem 1. Suppose marker observations are sampled independently and nD̄ → ∞, nn1 →
D̄


√
n2
ˆ
λ1 ∈ (0, 1), n → λ2 ∈ (0, 1), then nD̄ ∆ − ∆ converges to a mean 0 normal random
D̄

variable with variance σ 2, with
1)
2)
+ varλ(Q
if F̂ is the empirical CDF, where
(a) σ 2 = var (R1 (YD̄ ) − R2 (YD̄ )) + varλ(Q
1
2

Rz (YD̄ ) = P (Yz < YD̄ ) denotes the percentile value of the marker YD̄ from a control within
the z th case distribution, and
T
1)
2)
Σ(θ) ∂∆
+ varλ(Q
+ varλ(Q
if F is modeled parametrically, where Σ(θ)
(b) σ 2 = ∂∆
∂θ
∂θ
1
2


√
is the asymptotic variance of nD̄ θ̂ − θ and we assume that ∆ is differentiable with
ˆ comes from two sources, that due to sampling
respect to θ. Thus the variability of ∆
controls that form the reference distribution, and that due to sampling cases and calculating their percentile values given the reference distribution. In practice, we can use
 
d (Q̂1 )
d (Q̂2 )
d (Q1 )
d (Q2 )
ˆ
ˆ
var
∂∆
var(
c R̂1 (YD̄ ) − R̂2 (YD̄ )) + var
+
or
+ var
to
|Tθ=θ̂ Σ(θ̂) ∂∂θ∆ |θ=θ̂ + var
n1 /n
n2 /n
∂θ
n1 /n
n2 /n
D̄

D̄

D̄

D̄

consistently estimate σ 2 (where var
c indicates the sample variance estimate). Another way
to estimate σ 2 is to bootstrap, resampling subjects from the control and each case group
ˆ − ∆, we can construct a confidence interval for
separately. By calculating the variance of ∆
∆, and formally test for equality of E(Q1 ) and E(Q2).
In the ovarian cancer study (McIntosh et al., 2004), serum samples from 41 healthy
women, 24 women with benign ovarian tumors, and 66 women with clinically detected ovarian
cancer, were assayed for CA-125. Figure 1(a) displays the distribution of log(CA-125) in the
4
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three groups. The difference between the ovarian cancer group and the healthy group is
larger than the difference between the benign tumor group and the healthy group. We
also computed the percentile values of CA-125 in each of the case groups, using either the
empirical control distribution or under the assumption that log(CA-125) in controls follows a
normal distribution after box-cox transformation. Distributions of the estimated percentile
values are displayed by case group in Figure 1. Women with ovarian cancer appear to have
larger percentile values of CA-125 compared to women with benign tumors, suggesting it
better discriminates ovarian cancer than benign tumor from healthy women.
Let Q1 and Q2 be percentile values for women with benign tumors and women with
ovarian cancer, respectively. We calculated 95% CI for ∆, the expected difference in mean
percentile values between the two case groups. When F is estimated empirically, Q̂1 = 63.31,
ˆ = −26.86, and the 95% CI for ∆ is (−42.77, −10.94) based on the asymptotic
Q̂2 = 90.17, ∆
variance, and (−42.74, −10.97) based on the bootstrap variance. When F is estimated paraˆ = −25.47, and the 95% CI for ∆ is (−41.48, −9.46)
metrically, Q̂1 = 64.56, Q̂2 = 90.03, ∆
based on the asymptotic variance, and (−41.39, −9.56) based on the bootstrap variance. Inference based on the asymptotic and bootstrap variance agree fairly well here. The p-value
for comparing E(Q1) and E(Q2 ) (denoted as “unconditional”) is presented in Table 1. The
population mean percentile values are significantly different (at α = 0.01 level) between the
two case groups, regardless of how we model the marker distribution in controls. The ability
of CA-125 to identify ovarian cancer seems to be much better than is its ability to detect
benign tumors.

3.1.2 Conditional Test

When our objective is hypothesis testing as opposed to estima-

tion, we can consider testing for equality of mean percentile values conditional on the control
sample. We use the term “conditional” inference here. The advantage of the conditional
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approach is that it maintains independence among the estimated percentile values, allowing
standard two-sample tests for independent samples to be applied to compare case groups.
The following formal proposition is proved in supplementary appendices.
Proposition 1. Under H0 : Q1 =d Q2, if the support of the marker Y in each case group
is covered by its support in controls, then Y1 =d Y2 and Q̂1 and Q̂2 have the same conditional
distribution.
The implication of Proposition 1 is that if we reject the hypothesis that Q̂1 and Q̂2 have
the same conditional distribution, we can reject the null hypothesis that Q1 and Q2 have
the same distribution. That is, equal discriminatory performance is rejected. A common
way to test the equality of distributions is to test for equality of means. Earlier we used
the unconditional test to compare the means of Q1 and Q2 . In another words, we tested
whether E(∆) = 0 where variability enters through both case and control samples. Here
we compare the means of Q̂1 and Q̂2 conditioning on the control sample. That is we test
ˆ i , i = 1, ..., nD̄ ) = 0.
whether E(∆|Y
ˆ is:
Observe that conditional on the control sample, the variance of ∆
!
n1
n2
1 X
1 X
var
Q̂1j −
Q̂2j Yi , i = 1, ..., nD̄
n1 j=1
n2 i=1
=

var(Q̂1|Yi , i = 1, ..., nD̄) var(Q̂2|Yi , i = 1, ..., nD̄)
+
n1
n2

which can be consistently estimated by:
c Q̂2)
var(
c Q̂1) var(
+
.
n1
n2
ˆ can be estimated by:
On the other hand, the unconditional variance of ∆
var(
c Q̂1) var(
c Q̂2) var(
c R̂1 (YD̄ ) − R̂2 (YD̄ ))
+
+
n1
n2
nD̄
var(
c Q̂1) var(
c Q̂2)
≥
+
n1
n2
6
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As a result, the conditional test comparing the means of Q̂1 and Q̂2 is always more powerful
than the unconditional test. This is corroborated by results in the top row of Table 1.
According to Proposition 1, Q1 =d Q2 ⇔ Y1 =d Y2 . Therefore, an alternative way to
test H0 : Q1 =d Q2 is to compare the distributions of Y1 and Y2 , that is, the distributions
of raw marker measurements between the two case groups. Standard two-sample tests for
comparing two groups, such as the t-test,Wilcoxon rank sum test, or permutation test, all
can be used for this purpose. Tests based on raw marker measurements and tests based
on percentile values have the same type-I error under the null hypothesis H0 : Y1 =d Y2 or
H0 : Q1 =d Q2, but their powers may differ under different alternative hypotheses. In Table
1, we note that the test for equal means of Y1 and Y2 reaches the same conclusion as that
for equal means of Q̂1 and Q̂2. This might not be true in other circumstances, depending on
the particular control sample used as the reference. We do not include detailed illustrations
here.
In summary, to compare a marker’s ability to differentiate two different case groups from
the same control group, we can compare means of their percentile values Q1 and Q2. On
the one hand, if we are interested in constructing a confidence interval for E(Q1) − E(Q2),
we need to use unconditional inference that incorporates variability in controls as well as
cases. We derived corresponding variance expressions. On the other hand, if our objective is
simply to perform a hypothesis test for equality of the distributions of Q1 and Q2 , we should
use conditional methods because of their enhanced power.
3.2 Rank Statistics
The previous section deals with comparisons of mean percentile values. However, when
distributions of percentile values do not belong to the same location-scale family (as shown
in Figures 1(b) and 1(c)), the comparison between means does not tell the whole story about
the difference between distributions. This motivates comparing distributions of percentile

7

Hosted by The Berkeley Electronic Press

values using other types of test statistics that are not based on means. For example, we
can use rank-based statistics. The Wilcoxon rank sum test is often used for comparing
two groups of independent samples. For the problem at hand, we need to acknowledge the
correlation among Q̂0s when applying the Wilcoxon rank sum test to them.
In analogy with methods in the previous section, we can compare the ranks of Q̂1 and Q̂2
“unconditionally” or “conditionally”. Applying the Wilcoxon rank sum test unconditionally
to Q̂1 and Q̂2, the null hypothesis tested is P (Q̂1 > Q̂2) = P (Q̂1 < Q̂2), which holds
if Q1 =d Q2 according to Proposition 1. Comparing the ranks of Q̂1 and Q̂2 conditional
on the control sample, the null hypothesis tested is P (Q̂1 > Q̂2 |Yi , i = 1, ..., nD̄ ) = P (Q̂1 <
Q̂2|Yi , i = 1, ..., nD̄ ), which holds for all sets of control samples if Q1 =d Q2 . With conditional
testing, the observations are independent and so standard Wilcoxon rank sum test can be
applied. However, for the unconditional test, the variance of the Wilcoxon rank sum test
statistic must be estimated using the bootstrap, resampling from controls and each case
group.
In Table 1, both the conditional and unconditional Wilcoxon rank sum tests suggest
significant differences in the distributions of CA-125 percentile values between benign tumor
cases and ovarian cancer cases. Again, the conditional Wilcoxon rank sum test applied to
Q̂ is more powerful than the unconditional test since it does not involve variability in the
control sample.
According to Proposition 1, we can also apply the Wilcoxon rank sum test to the raw
marker measurements between the two case groups to test the null hypothesis Q1 =d Q2.
Consider the comparison between the Wilcoxon rank sum test applied to Y1 and Y2 and
that applied to Q̂1 and Q̂2. If the transformation from Y to the corresponding Q̂ does not
change each observation’s rank in the sample, then the rank based statistic is invariant to
this transformation. This happens when F the marker distribution in controls is modeled
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as a parametric family with strictly monotone increasing distribution function, but does not
necessarily happen when F is estimated nonparametrically. In the latter case, the Wilcoxon
rank sum test applied to Q̂1, Q̂2 can be different from that applied to Y1 , Y2. Depending on
their placement with respect to the control sample, the two groups of case marker measurement Y may be ”squeezed” differently by the transformation to Q̂. In particular, more ties
may be created with the empirical CDF transformation. The increase in the number of ties
will (1) potentially affect the value of the Wilcoxon rank sum test statistic (depending on
how many pairs of Y1i > Y2j or Y1i < Y2j lead to Q̂1j = Q̂2j ) and (2) reduce the variance
of the test statistic. In the ovarian cancer data, the Wilcoxon rank sum test applied to Q̂0s
and that applied to Y 0 s lead to the same conclusion (Table 1), but there are situations when
different conclusions can be reached (results not shown).
We note that the variance of the Wilcoxon rank sum test statistic gets smaller as the
number of ties in the data increases. Using the nonparametric bootstrap tends to create ties
in the marker sample. Then when calculating percentile values, ties are created as a result of
ties in the control and case samples when F is estimated empirically, or as a result of ties in
case samples when F is estimated parametrically. This increase in ties due to sampling with
replacement has the potential to lead to under-estimation of the variance. The severity of
this problem depends on the sample size and the distribution of percentile values. We found
in limited simulation studies that for small sample sizes and good classification accuracy,
applying the Wilcoxon rank sum test with nonparametric bootstrap to Q̂ can lead to anticonservative type-I error, especially when F is estimated nonparametrically. A solution to
this problem is to use the smoothed bootstrap (Silverman, 1986; Silverman and Young,
1987). The idea is to simulate from smoothed distributions to avoid ties during resampling.
There has been little systematic investigation about the choice of optimal bandwidth. We
explored several bandwidths in simulation studies and found that the bandwidth that covers

9

Hosted by The Berkeley Electronic Press

around 40% of the total sample works reasonably well.
In summary, to compare the discriminatory performance of a marker across different case
groups using rank based tests, we recommend (1) transforming the data to the estimated
percentile values because the resulting test based on Q̂ is more relevant to differences in
diagnostic accuracies than differences on the raw marker distribution scale, and (2) using
the conditional rather than unconditional Wilcoxon rank sum test because the conditional
test can be performed with standard statistical software and is more powerful, whereas the
unconditional test calls for smoothed bootstrap for variance estimation and does not have a
sound theoretic basis for bandwidth selection.
3.3 Adjusting for Covariates
Suppose the biomarker distribution in controls varies with a covariate X, then the appropriate reference distribution should depend on X. We define the covariate specific percentile
value
QX = 100 × F (Y |X)
where F (Y |X) is the cumulative distribution function of the marker in the control population
with covariate value X. This is standard practice in clinical medicine for anthropometric
measurements. For example, the percentiles of height for children are age and gender specific
because these factors affect height in normal healthy children.
To compare women with benign tumor and women with ovarian cancer, we can evaluate
the covariate specific percentiles values for each case group and compare them using twosample statistics based on sample means or ranks as developed in section 3.1 and 3.2. Is
covariate adjustment important? The answer is ”potentially yes”. Suppose for example that
X is age and that in controls older age is associated with larger values of the biomarkers.
If women with ovarian cancer tend to be older than women with benign tumor, one would
observe a difference in discriminatory performance that is simply due to age. Using age
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adjusted biomarker percentiles is a simple way to eliminate such confounding.
If X is discrete and there are a lot of controls per X category, a nonparametric approach to
estimating F (Y |X) can be taken. Otherwise a parametric model is employed. With z = 1, 2,
let QzX (Q̂zX ) be the (estimated) covariate specific percentile value for an observation in case
ˆ = Q̂1X − Q̂2X . When covariate X is discrete
group z. Let ∆ = E(Q1X ) − E(Q2X ) and ∆
with K categories, let nD̄k be the number of controls, and nzk be the number of z th type of
cases in the k th covariate category, k = 1, ..., K.
Theorem 2. Suppose nD̄ → ∞, nn1 → λ1 ∈ (0, 1), nn2 → λ2 ∈ (0, 1). Suppose when X is
D̄

nD̄k
nD̄

D̄

n1k
n1

n2k
n2

→ pD̄k ∈ (0, 1),
→ p1k ∈ (0, 1), and
→ p2k ∈ (0, 1), k = 1, ..., K. Then
discrete,


√
ˆ − ∆ converges to a mean 0 normal random variable with variance σ 2, where
nD̄ ∆


P var(Rk1 (YD̄k )) var(Rk2 (YD̄k ))
2
+ p /p2
+ varλ(Q1 1X ) + varλ(Q2 2X ) if F (Y |X) is modeled
(a) σ = k
pD̄k /p21k
D̄k
2k


with the empirical CDF, where Rkz YD̄k = P Yzk < YD̄k and the k superscript indicates
cases and controls in covariate category k.
+ varλ(Q1 1X ) + varλ(Q2 2X ) if F (Y |X) is modeled parametrically, where

√ 
Σ(θ) is the asymptotic variance of nD̄ θ̂ − θ and we assume that ∆ is differentiable with
(b) σ 2 =

∂∆ T
Σ(θ) ∂∆
∂θ
∂θ

respect to θ and(that F = {Fθ (y|x) : θ ∈ Θ}
) is a Donsker class (Donsker, 1952). In practice,
d (R̂k (Y k ))
d (R̂k (Y k ))
P var
var
d (Q̂1X )
d (Q̂2X )
we can use k nD̄k 1n1kD̄2 + nD̄k 2n2kD̄2 + var
+ var
or
n1 /nD̄
n2 /nD̄
/
/
nD̄
n1
nD̄
n2
 
d (Q̂1X )
d (Q̂2X )
ˆ
ˆ
∂∆
|Tθ=θ̂ Σ(θ̂) ∂∂θ∆ |θ=θ̂ + var
+ var
to consistently estimate σ 2.
∂θ
n1 /n
n2 /n
D̄

D̄

To illustrate the comparison of covariate specific percentile values between two case
groups, we simulated a continuous covariate X for the ovarian cancer data. X is generated
to be positively associated with both CA-125 and disease status, X ∼ N (µ, σ) where µ = 10×
log {5 × I(benign tumors) × I(log(CA-125) > 2.2) + .8 × I(ovarian cancer) + 1.5 × log(CA-125)}
and σ = 4. Figure 2 shows the distribution of log(CA-125) in healthy women, women with
benign ovarian tumors, and women with ovarian cancer ignoring covariate X (marginal distributions, where F is modeled parametrically) or when X is equal to its (.25, .5, .75) quantiles
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in the whole sample. It appears that the distribution of log(CA-125) in controls varies with
X. Moreover, the separations between controls and case groups differ with X. To calculate
covariate-specific percentile values, we assume the distribution of log(CA-125) in controls
conditional on a specific covariate value is normally distributed. The mean is modeled as
a cubic B-spline in X, with pre-chosen knots at the (.25, .5, .75) quantiles in the control
sample.
Figure 3 plots the distributions of unadjusted and covariate specific percentile values of
CA-125 for women with benign tumors and women with ovarian cancer. It appears that
adjusting for the covariate X reduces the separation between women with benign tumors
and healthy women, while the separation between women with ovarian cancer and healthy
women is unchanged. Indeed the covariate adjusted percentile values have an approximately
uniform distribution for women with benign tumors indicating that their distribution is the
same as that for normal healthy controls. Therefore covariate adjustment appears to be
desirable in this setting. After covariate adjustment, CA-125 picks up fewer benign tumor
cases while maintaining its ability to identify ovarian cancer cases.
We now formally compare the two groups of cases in regards to their covariate specific
percentile values. All of the unconditional tests described in section 3.1 and 3.2 can be applied. P-values comparing E(Q1X ) and E(Q2X ) are 0.0002 based on the asymptotic variance
and 0.0004 based on the bootstrap variance, while for the Wilcoxon rank sum test applied
to Q̂1X and Q̂2X the p-value is less than 0.0001. All tests suggest that CA-125 has better
discriminatory performance for identifying ovarian cancer compared to benign tumors. We
also estimate the mean covariate specific percentile values for the two case groups and their
difference ∆. As expected for benign tumors, Q̂1X is close to the uninformative marker
value of 50 (Q̂1X = 50.13), because their distribution is close to uniform (0,100). In the
ovarian cancer group, Q̂2X = 88.10 which is similar to the mean unadjusted percentile val-
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ˆ = −37.96, with 95% CI
ues Q̂2 = 90.17. The difference in covariate adjusted means is ∆
(−57.76, −18.16) based on the asymptotic variance expression and (−58.79, −17.13) based
on the bootstrap variance. Observe that Q̂1X − Q̂2X is larger than Q̂1 − Q̂2 .
In summary, when the marker distribution in controls varies with a covariate, covariate
specific percentile values can be calculated to eliminate potential confounding. Two groups
of cases can then be compared using mean or rank based statistics. This provides a covariate
adjusted comparison of the discriminatory capacity of the marker.
4.

Comparing Markers

Next consider the comparison of two markers with respect to their diagnostic accuracy.
Suppose we have two types of subjects, cases and controls, with two markers measured on
each subject. Let nD , nD̄ be the number of cases and controls respectively. Let Fz , z = 1, 2 be
the distribution function for the z th marker in controls, and let Qz (Q̂z ) denote the (estimated)
case percentile value for the z th marker. Observe that each marker is standardized with
respect to its own control reference distribution. Even though the raw marker values may
be in different units, the transformation to percentile values put them on the same scale.
4.1 Using Means
For each case, one can compare their percentile value standardized markers Q1 and Q2. If
Q1 tends to be larger than Q2 then Q1 is the better marker. Formally, let ∆ = E(Q1 − Q2) =
E(Q1) − E(Q2). The difference in sample means can serve as the basis of a test statistic
ˆ = Q̂1 − Q̂2 .
∆
In this two-marker setting, the correlation between estimated percentile values comes
from two sources. First, two marker measurements measured on the same subject are correlated. Second for any particular marker, the estimated percentile values are correlated due
to sampling variability in the controls used to calculate the reference distribution. We need
to acknowledge this variation in making inference.

13
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Theorem 3. Suppose

nD
nD̄

→ λ as nD̄ → ∞, then



√
ˆ − ∆ converges to a mean 0
nD̄ ∆

normal random variable with variance σ 2, where
(a) σ 2 = var(R1 (Y1D̄ ) − R2 (Y2D̄ )) + var(Qλ1−Q2 ) if Fz is estimated with the empirical
CDF, where YzD̄ and YzD are the measurements of the z th marker from a control and a case
respectively, and Rz (YzD̄ ) = P (YzD < YzD̄ ) is the percentile value of the z th marker from a
control in its case distribution (Delong et al., 1988),
T
Σ(θ) ∂∆
+ var(Qλ1 −Q2 ) if Fz is modeled parametrically with parameter θz ,
(b) σ 2 = ∂∆
∂θ
∂θ

√ 
θ = (θ1, θ2 ), Σ(θ) is the asymptotic variance of nD̄ θ̂ − θ and we assume ∆ is differentiable with respect to θ. In practice, σ 2 can be consistently estimated by var(
c R̂1 (Y1D̄ ) −
 T
d
d 1 −Q̂2 )
ˆ
ˆ
1 −Q̂2 )
R̂2 (Y2D̄ )) + varn(DQ̂/n
in (a) and ∂∂θ∆ Σ(θ̂) ∂∂θ∆ |θ=θ̂ + varn(DQ̂/n
in (b). We could also
D̄

D̄

2

bootstrap to estimate σ , resampling subjects from case and control groups separately.
Observe that, for this two-marker problem, the conditional test is no longer applicable.
Even if the distributions of Q1 and Q2 are the same, the distributions of Q̂1 and Q̂2 conditional on the particular control sample will not necessarily be equal. That is, testing the
null hypothesis that Q̂1 |YD̄i , i = 1, ..., nD̄ =d Q̂2|YD̄i , i = 1, ..., nD̄ is not equivalent to testing
the null hypothesis that Q1 =d Q2 .
The dataset we use for illustration here is from a pancreatic cancer serum biomarker
study (Wieand et al., 1989). This is a case-control study including 90 cases with pancreatic
cancer and 51 controls that had pancreatitis. Serum samples from each patient were assayed
for CA-19-9, a carbohydrate antigen, and CA-125, a cancer antigen.
Figure 4(a) shows the probability distribution of log(CA-19-9) and log(CA-125) for controls and cases separately. Also displayed are the distributions of the estimated percentile
values in cases for each marker, with Fz , z = 1, 2 estimated empirically in Figure 5(b), and
under the normal assumption after box-cox transformation in Figure 5(c). Clearly, the distribution of the estimated percentile values for CA-19-9 is shifted to the right compared
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with CA-125, indicating that it is a better biomarker. In other words, more cases have high
percentile values for CA-19-9 than for CA-125.
Next consider the mean percentile values. When Fz is estimated empirically, Q̂1 = 86.23
ˆ = 15.53. The corresponding 95% CI for ∆
for CA-19-9, Q̂2 = 70.70 for CA-125, and ∆
is (4.34, 26.73) using the asymptotic variance and similar, (4.37, 26.70), using the bootstrap
variance. When Fz is estimated parametrically, results are similar: Q̂1 = 86.07, Q̂2 = 71.09,
ˆ = 14.97. The corresponding 95% CI for ∆ is (3.80, 26.15) using the asymptotic
and ∆
variance and (3.57, 26.38) using the bootstrap variance. The differences are highly significant
(Table 2). CA-19-9 is a better biomarker than CA-125 for pancreatic cancer.
In summary, to compare the diagnostic accuracies of two markers, we can use the controls
to transform them to the percentile value scale and compare the percentile values in cases
with the difference in means. If nD̄ = ∞, this is essentially a paired t-test. If nD̄ < ∞, the
paired t-test needs to be modified to accommodate the additional variability in the estimated
control marker distributions.
4.2 Using Rank Statistics
Rank based tests provide another avenue to compare the distributions of percentile values.
In particular, when Q̂1 and Q̂2 have similar expectations, a test comparing their means
(section 4.1) will have low power. Rank based tests may be more powerful. Due to the
complicated correlation structure, standard variance formulae for rank test statistics no
longer apply. Instead, we use the bootstrap method to calculate their variances. Moreover,
as discussed earlier, the conditional test is not applicable for the two marker problem. So only
the unconditional test is discussed here. Heuristic proofs of the following three propositions
are given in supplementary appendices.
Proposition 2.
Under H0 : Q1 =d Q2 , we have Q̂1 =d Q̂2 when Fz is estimated empirically.
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Proposition 3.
Let Uj = Q̂1j − Q̂2j , j = 1, ..., nD . Let T and S be the Wilcoxon signed rank test statistic
and the Sign test statistic respectively. Under H0 : Q1 =d Q2, we have E(T ) =
1
2

nD +1
, E(S)
4

=

when Fz is estimated empirically.
Proposition 4

o

n

n

o

Let rk be the rank of Q̃k where Q̃k , k = 1, ..., 2nD = Q̂1j , j = 1, ..., nD , Q̂2j , j = 1, ..., nD .
P D
Let W = nk=1
rk be the Wilcoxon rank sum test statistic. Then under H0 : Q1 =d Q2,
E(W ) =

nD (2nD +1)
12

when Fz is estimated empirically.

We expect the corresponding results in propositions 2-4 to hold asymptotically when Fz
is estimated parametrically.
Under H0 : Q1 =d Q2, or equivalently Q̂1 =d Q̂2 (according to Proposition 2), the
expectation of the Wilcoxon rank sum test statistic, W , applied to Q̂1 and Q̂2 is the same
as E(W ) when W is applied to two groups of independent observations from the same
distribution (Proposition 4); and the expectations of the Wilcoxon signed rank test statistic
T and the Sign test statistic S applied to Q̂1 and Q̂2 is the same as E(T ) and E(S) when
those test statistics are applied to a paired sample where the two members in each pair have
the same marginal distribution (Proposition 3). Therefore, to test H0 : Q1 =d Q2, we can
use the rank based test statistics applied to Q̂1 and Q̂2 , bootstrapping the variance. Here
we face the same concern about under-estimation of the variance as in section 3.2. We use
a smoothed bootstrap to minimize this problem. Asymptotic distribution theory appears to
be very challenging. Table 2 displays p-values based on the rank tests for comparing the case
distributions of CA-19-9 percentile values with CA-125 percentile values, using a bandwidth
covering approximately 40% sample points in the smoothed bootstrap. All of these tests
suggest a highly significant difference.
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4.3 Adjusting for Covariates
We argued earlier that adjusting for covariates may be important when comparing two
case groups. This is also potentially important when comparing two biomarkers. Suppose
for example that biomarker values in the control group vary with study site in a multicenter study. Such might occur if collection or processing procedures differed across sites.
If the site specific control populations are pooled to form a reference set, the distribution
of the case percentiles may be more diffuse than if the site specific controls are used for
reference (see the right side of Figure 5 for an example). Biomarker performance can appear
to be worse than it is by using a pooled reference set. Markers may differ in regards to
this phenomenon. Processing techniques that vary across sites may affect one marker but
not another. Covariate effects on reference distributions of biomarkers therefore can bias
the comparison of markers unless proper adjustment is undertaken. The use of covariate
specific percentile values is a means to avoid such bias. In summary, covariate adjustment
is required for covariates that affect the marker in controls. Note that pertinent covariates
may be different for different markers.
Let QzX (Q̂zX ) be the covariate specific percentile value (estimated) for the z th marker,
ˆ = Q̂1X − Q̂2X . When the covariate X is discrete
z = 1, 2, ∆ = E(Q1X ) − E(Q2X ), and ∆
with K categories, let nD̄k and nDk be the numbers of controls and cases in the k th covariate
category, k = 1, ..., K.

pD̄k

Theorem 4 Suppose nD̄ → ∞, nnD → λ ∈ (0, 1), and for discrete covariate, nnD̄k →
D̄
D̄


√
ˆ − ∆ converges to a mean 0
∈ (0, 1), nnDk
→ pDk ∈ (0, 1), k = 1, ..., K, then nD̄ ∆
D

normal random variable with variance σ 2, where
P var(Rk1 (Y1kD̄ )−Rk2 (Y1kD̄ )) var(Q1X −Q2X )
(a) σ 2 = k
+
if F (Y |X) is estimated empirically, where
λ
p /p2
D̄k

Rkz (YzkD̄ )

=

k
P (YzD

<

YzkD̄ )

Dk

is the percentile value for a control using his covariate specific case

distribution as the reference for z th marker in the k th covariate category,
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∂∆ T
∂θ

−Q2X )
Σ(θ) ∂∆
+ var(Q1X
if F (Y |X) is modeled parametrically for marker z
∂θ
λ

√ 
with parameter estimate θz , θ = (θ1 , θ2) and Σ(θ) is the asymptotic variance of nD̄ θ̂ − θ ,

(b) σ 2 =

we assume that ∆ is differentiable with respect to θ and that F = {Fθ (y|x) : θ ∈ Θ} is a
P var
d (R̂k (Y k ))−R̂k (Y k ))
1 1D̄
2
 2D̄ +

Donsker class. In practice, σ 2 can be consistently estimated by k
nD̄k
nDk 2
/
nD̄
nD
 
d (Q̂1X −Q̂2X )
d (Q̂1X −Q̂2X )
ˆX
ˆ
var
var
∂∆
∂∆
T
in (a) and by ∂θ |θ=θ̂ Σ(θ̂X ) ∂θ |θ=θ̂ +
in (b).
nD /n
nD /n
D̄

D̄

To illustrate the use of adjusting for covariates when comparing markers, we simulate a
discrete covariate X for the pancreatic cancer data. We set X to 1 for those with CA-125
above its median in the data, and 0 otherwise. 14 out of 51 (27.4%) controls and 57 out of
90 (63.3%) cases have covariate X = 1.
Figure 5 shows the probability distributions of log(CA-19-9) and log(CA-125) in control
and case samples respectively within each covariate category. First we look at CA-19-9,
it seems that the covariate does not have a dramatic influence on the reference control
distribution. Thus covariate adjustment does not appear to be warranted for CA-19-9.
On the other hand, covariate adjustment is warranted for CA-125. Within each covariate
category, there is not much difference between cases and controls. However, since CA-125
is positively associated with the covariate and the case group has a higher percentage than
controls of subjects with covariate X = 1, when data are pooled over covariate categories,
the distribution of cases shifts to the right compared to the distribution of controls. In other
words X is a confounder for the CA-125 marker.
Covariate specific percentile values for CA-19-9 (Q̂1X ) and CA-125 (Q̂2X ) in cases were
calculated within each covariate category. Figure 6 plots the distributions. For CA-19-9,
the case distribution of the estimated covariate specific percentile values is similar to that
of the marginal percentile values, whereas for CA-125, covariate adjustment suggests poorer
performance for CA-125 than the performance that ignores the covariate. That is, the
confounding effect of X is removed by covariate adjustment.
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When F (Y |X) is estimated empirically for each marker, Q̂1X = 87.25 for CA-19-9,
ˆ = 33.40. The corresponding 95% CI for ∆ is
and Q̂2X = 53.85 for CA-125, with ∆
(20.04, 46.76) using the asymptotic variance and (20.83, 45.97) using the bootstrap variance.
When F (Y |X) is estimated parametrically for each marker, Q̂1X = 87.09 for CA-19-9, and
ˆ = 32.89. The corresponding 95% CI for ∆ is (18.97, 46.81)
Q̂2X = 54.20 for CA-125, with ∆
using the asymptotic variance and (20.38, 45.40) using the bootstrap variance. We compare
Q̂1X and Q̂2X using mean and rank based tests as discussed in sections 4.1 and 4.2 (Table
2). CA-19-9 appears to be a much better marker than CA-125 for identifying pancreatic
cancer, especially after adjusting for the covariate.
5.

Relationships with ROC analysis

Our approach to evaluating the capacity of a marker to distinguish cases from a reference
set of controls is to use the reference control marker distribution to standardize marker
values for cases. If these percentile values tend to be high for many cases, the marker’s
discriminatory capacity is good. We noted earlier that the approach is intuitive and is
used in some applications (Frischancho, 1990; McIntosh et al., 2004). Interestingly it is
equivalent to ROC analysis, which plays a central role in biomarker evaluation (Baker,
2003). The equivalence has been noted previously (Pepe and Cai, 2004; Pepe and Longton,
2005). In particular since the ROC curve, a plot of T P R = P (Y > c|D = 1) versus
F P R = P (Y > c|D = 0), can be written as

ROC(t) = P (Y > S −1 (t)|D = 1) t ∈ (0, 1)
= P (S(Y ) < t|D = 1)
where S = 1 − F , the ROC curve can be interpreted as the CDF of 1 − F (Y ) in cases.
Thus comparing case distributions of biomarker percentile values, 100 × F (Y ), is entirely
19
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equivalent to comparing ROC curves. Empirical ROC curves for the ovarian and pancreatic
cancer dataset are shown in Figure 7.
Some of the procedures presented in sections 3 and 4 are alternative representations of
existing procedures for comparing ROC curves while some are new procedures. Using the
fact that the mean of a random variable is equal to the area under its survival function, the
average of case percentile values can be represented in terms of the area under the ROC
curve (AUC)(Bamber, 1975),
AU C = E(Q)/100.
Thus comparisons based on mean percentile values are equivalent to comparisons of AUCs,
the classical approach to comparing ROC curves.
Hanley and Hajian-Tilaki (1997) represented the empirical AUC as the sample mean of
case percentile values with F estimated empirically. The asymptotic results in Theorems
1(a) and Theorem 2(a) are results for empirical AUC differences that have been previously
reported (Sukhatme and Beam, 1994; Delong et al., 1988). However, their semi-parametric
counterparts in Theorems 1(b) and 2(b) have not. Li et al. (1996) studied semi-parametric
estimation of the ROC curve when the case distribution is modeled parametrically and the
control distribution is modeled empirically. We did the reverse in this paper using a flexible smooth form for the reference distribution of control biomarker values. The Box-Cox
family has precedent in modeling the reference distribution for anthropometric measures
(Cole, 1990). Returning to the asymptotic results in Theorem 1(a) and 2(a), in contrast to
Sukhatme and Beam (1994) and similar to Hanley and Hajian-Tilaki (1997), we reparameterized the variances in terms of percentile values in this report, which we feel is a more
intuitive way to understand the components of the variance.
A problem with comparing diagnostic accuracy of two tests using the area under the
ROC curve is the lack of power to detect the difference in ROC curves when they have
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the same area under the curve. As pointed out by Swets (1986), ROC curves are typically
asymmetric, and two ROC curves with different asymmetries might cross each other but
have the same AUC. Venkatraman and Begg (1996) developed a permutation test based
procedure to compare two ROC curves with paired data. Extension of the permutation test
to the case of continuous unpaired data was also proposed (Venkatraman, 2000). Extension
to comparisons among more than two tests, however, might be computationally intensive.
The rank statistics described in sections 3.2 and 4.2 compare ROC curves as well. These
can be interpreted as new ROC analysis techniques and provide an alternative way to compare ROC curves. On the other hand, their interpretation as rank statistics to compare
distributions of standardized biomarkers in cases is equally valid and may be preferred by
some. The generalization to comparing distributions of multiple standardized biomarkers is
also tenable (Cuzick 1985; Kruskal and Wallis, 1952).
The concept of covariate adjustment has only recently been developed for ROC analysis.
The use of covariate specific percentiles provides a simple intuitive and easily implemented
approach to adjust for covariates. Interestingly, arguments similar to those above prove
that the distribution of covariate specific placement values, 1 − Q/100, in cases, is the
covariate adjusted ROC curve, AROC(t), proposed by Janes and Pepe (2006, 2007). Thus,
our methods for comparing distributions of covariate specific percentiles can be interpreted
as methods to compare covariate adjusted ROC curves. Formal methods for comparing
covariate adjusted ROC curves have not been available heretofore. Our methods based on
mean covariate specific percentiles compare areas under the covariate adjusted ROC curves
while methods based on ranks provide an alternative approach.
6.

Concluding Remarks

Standardizing a biomarker or diagnostic test to a reference population of controls is not an
entirely new concept (Frischancho, 1990; McIntosh et al. 2004). However it is not yet a
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standard approach to biomarker evaluation. We suspect two reasons. First, ROC analysis
has become the standard of practice (Baker, 2003), and second, formal methods have not
been available for statistical inference that properly take account of sampling variability in
the reference distribution. This paper provides remedies by providing methods for statistical
inference and by noting the approach is interchangeable with ROC analysis. We feel that the
approach should be encouraged because of its conceptual simplicity, putting ROC analysis
within mainstream familiar data analytic methods.
Equally important, the approach opens up new avenues for evaluating biomarkers and diagnostic tests. For example, covariate adjustment is naturally handled within this framework.
We illustrated that covariate adjustment can be important when comparing biomarkers or
in comparing the performance of a biomarker in two populations. Pepe and Cai (2004) and
Cai (2004) already showed how ROC regression can be accomplished by performing regression analysis of case standardized marker values. In the context of evaluating biomarkers of
event time outcomes one might use the risk set at time t to standardize the biomarker for the
subject that fails at t (the case). Interestingly, it can be shown that the distribution of such
standardized values is closely related to the time dependent ROC curves recently developed
by Heagerty and Zheng (2005). We hope that the methods presented here will encourage use
of the percentile value standardized approach in practice and encourage further development
of new techniques for biomarker evaluation.
7.
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Figure 1. (a) Distributions of log(CA-125) in healthy women, women with benign ovarian
tumors, and women with ovarian cancer. (b),(c) Distributions of estimated percentile values
in benign tumor cases and ovarian cancer cases. Percentile values are calculated with the
empirical distribution of CA-125 in controls in (b). The distribution of CA-125 in controls
is assumed to be normal after a Box-Cox transformation in (c).
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Figure 2. Distributions of log(CA-125) in healthy women, women with benign ovarian
tumors, and women with ovarian cancer for specified covariate value and marginally.
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Figure 3. Distributions of estimated percentile values of CA-125 for women with benign
ovarian tumors, and women with ovarian cancer. Here ‘cov-adjusted’ indicates that covariate
specific control reference distributions were employed, while ‘marginal’ indicates that the
entire set of controls were used as a single reference group..
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Figure 4. (a) Distributions of log(CA-19-9) and log(CA-125) in controls and cases, (b)
distributions of estimated case percentile values when control distributions are estimated
empirically, and (c) distributions of estimated case percentile values when control distributions are assumed to be normal after the Box-Cox transformation.
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covariate category and marginally.
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Figure 6. Distributions of estimated case percentile values of CA-19-9 and CA-125. Here
‘cov-adjusted’ indicates that covariate specific control reference distributions were employed,
while ‘marginal’ indicates that the entire set of controls were used as a single reference group.
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and CA-125 in pancreatic cancer data (b).
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Table 1
p-value of tests comparing case percentile value distributions between benign tumor cases
and ovarian cancer cases. nD̄ = 41, n1 = 24, n2 = 66. Tests comparing raw marker values
between benign tumor cases and ovarian cancer cases yielded p < 0.0001 for both the t-test
and the Wilcoxon rank sum test.
Unconditional
Test

F̂ empirical

Conditional

F̂ parametric

F̂ empirical

F̂ parametric

Asym1 Boot2

Asym Boot

Asym

Boot

Asym

Boot

Mean

0.0009 0.0006

0.0018 0.0013

0.0005

0.0003

0.0012

0.0009

Rank

-

< 0.0001

< 0.0001s

< 0.0001

< 0.0001s

< 0.0001s

-

< 0.0001s

Asym1 : asymptotic variance
Boot2: nonparametric bootstrap variance or smoothed bootstrap variance (s )
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Table 2
p-value for comparing percentile value distributions between CA-19-9 and CA-125.
nD̄ = 51, nD = 90
Test Statistic

F̂ empirical CDF
Asym1

Boot2

F̂ parametric
Asym

Boot

Marginal
Mean Difference

0.007

0.007

0.009

0.01

WRS3

-

< 0.0001s

-

0.0006s

WSR4

-

< 0.0001s

-

0.0001s

Sign5

-

< 0.0001s

-

< 0.0001s

Covariate Adjusted
Mean Difference

< 0.0001

< 0.0001

< 0.0001

< 0.0001

WRS

-

< 0.0001

-

< 0.0001

WSR

-

< 0.0001

-

< 0.0001

Sign

-

< 0.0001

-

< 0.0001

Asym1 : asymptotic variance
Boot2: nonparametric bootstrap variance, or smoothed bootstrap variances
WRS3 : the Wilcoxon rank sum test statistic
WSR4 : the Wilcoxn signed rank test statistic
Sign5 : the Sign test statistic
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